The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients
Open accessAbstract
BACKGROUND: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy. We conducted a randomized, double-blind, clinical trial comparing everolimus with azathioprine in recipients of a first heart transplant. METHODS: A total of 634 patients were randomly assigned to receive 1.5 mg of everolimus per day (209 patients), 3.0 mg of everolimus per day (211 patients), or 1.0 to 3.0 mg of azathioprine per kilogram of body weight per day (214 patients), in combination with cyclosporine, corticosteroids, and statins. The primary efficacy end point was a composite of death, graft loss or retransplantation, loss to follow-up, biopsy-proved acute rejection of grade 3A, or rejection with hemodynamic compromise. RESULTS: At six months, the percentage of patients who had reached the primary efficacy end point was significantly smaller in the group given 3.0 mg of everolimus (27.0 percent, P<0.001) and the group given 1.5 mg of everolimus (36.4 percent, P=0.03) than in the azathioprine group (46.7 percent). Intravascular ultrasonography showed that the average increase in maximal intimal thickness 12 months after transplantation was significantly smaller in the two everolimus groups than in the azathioprine group. The incidence of vasculopathy was also significantly lower in the 1.5-mg group (35.7 percent, P=0.045) and the 3.0-mg group (30.4 percent, P=0.01) than in the azathioprine group (52.8 percent). The rates of cytomegalovirus infection were significantly lower in the 1.5-mg group (7.7 percent, P<0.001) and the 3.0-mg group (7.6 percent, P<0.001) than in the azathioprine group (21.5 percent). Rates of bacterial infection were significantly higher in the 3.0-mg group than in the azathioprine group. Serum creatinine levels were also significantly higher in the two everolimus groups than in the azathioprine group. CONCLUSIONS: Everolimus was more efficacious than azathioprine in reducing the severity and incidence of cardiac-allograft vasculopathy, suggesting that everolimus therapy may alleviate this serious problem.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Mintz, G. S., Nissen, S. E., Anderson, W. D., Bailey, S. R., Erbel, R., Fitzgerald, P. J., Pinto, F. J., Rosenfield, K., Siegel, R. J., Tuzcu, E. M., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01175-5 · Cited by 2,185
Self-citationBillingham, M. E., Cary, N. R. B., Hammond, M. E. H., Kemnitz, J., Marboe, C. C., Mccallister, H. A., Snovar, D. C., Winters, G. L., & Zerbe, A. (1990) · PubMed · Cited by 1,490
Effect of pravastatin on outcomes after cardiac transplantation
Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301
Self-citationCytomegalovirus Infection Is Associated With Cardiac Allograft Rejection and Atherosclerosis
Grattan, M. T. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420240075030 · Cited by 968
IMMUNOPHARMACOLOGY OF RAPAMYCIN
Abraham, R. T., & Wiederrecht, G. J. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.483 · Cited by 653
A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1
Kobashigawa, J., Miller, L., Renlund, D., Mentzer, R., Alderman, E., Bourge, R., Costanzo, M., Eisen, H., Dureau, G., Ratkovec, R., et al. (1998) · Transplantation · doi:10.1097/00007890-199808270-00016 · Cited by 615
Self-citationSDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Pharmacological Properties In Vitro and In Vivo
Schuler, W., Sedrani, R., Cottens, S., H??berlin, B., Schulz, M., Schuurman, H.-J., Zenke, G., Zerwes, H.-G., & Schreier, M. H. (1997) · Transplantation · doi:10.1097/00007890-199707150-00008 · Cited by 533
Costanzo, M. R., Naftel, D. C., PRITZKER, M. R., Heilman, J. K., BOEHMER, J. P., Brozena, S. C., DEC, G. W., Ventura, H. O., Kirklin, J. K., Bourge, R. C., et al. (1998) · PubMed · Cited by 460
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., Seidel, D., & Reichart, B. (1997) · Circulation · doi:10.1161/01.cir.96.5.1398 · Cited by 444
Fang, J. C., Kinlay, S., Beltrame, J., Hikiti, H., Wainstein, M., Behrendt, D., Suh, J., Frei, B., Mudge, G. H., Selwyn, A. P., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08154-0 · Cited by 293
Kahan, B. D., Julian, B. A., Pescovitz, M. D., Vanrenterghem, Y., & Neylan, J. (1999) · Transplantation · doi:10.1097/00007890-199911270-00016 · Cited by 279
Rapamune (Sirolimus, Rapamycin): An Overview and Mechanism of Action
Sehgal, S. N. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199512000-00019 · Cited by 279
SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Synergism with Cyclosporine
Schuurman, H.-J., Cottens, S., Fuchs, S., Joergensen, J., Meerloo, T., Sedrani, R., Tanner, M., Zenke, G., & Schuler, W. (1997) · Transplantation · doi:10.1097/00007890-199707150-00007 · Cited by 248
Abraham, R. T. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80172-6 · Cited by 192
Keck, B. M., Bennett, L. E., Fiol, B., Daily, O. P., Novick, R. J., & Hosenpud, J. D. (1995) · PubMed · Cited by 182
Rickenbacher, P. R., Pinto, F. J., Lewis, N. P., Hunt, S. A., Alderman, E. L., Schroeder, J. S., Stinson, E. B., Brown, B. W., & Valantine, H. A. (1995) · Circulation · doi:10.1161/01.cir.92.12.3445 · Cited by 180
Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility.
Costanzo-Nordin, M. R. (1992) · PubMed · Cited by 116
KIMBALL, P. M., Kerman, R. H., & KAHAN, B. D. (1991) · Transplantation · doi:10.1097/00007890-199102000-00041 · Cited by 89
Impact of intravascular ultrasound in understanding transplant coronary artery disease
Kapadia, S. R., Nissen, S. E., & Tuzcu, E. M. (1999) · Current Opinion in Cardiology · doi:10.1097/00001573-199903000-00011 · Cited by 88
Self-citationNoninvasive assessment of transplant-associated arteriosclerosis
Fang, J. C.-T., Rocco, T. A., Jarcho, J. A., Ganz, P., & Mudge, G. H. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70062-6 · Cited by 52
Young, J. B. (1999) · Circulation · doi:10.1161/01.cir.100.5.458 · Cited by 34
Gummert, J. F., Ikonen, T. S., & Morris, R. E. (2001) · Springer eBooks · doi:10.1007/978-1-4615-1649-1_11 · Cited by 2
Cited by
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Self-citationNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Self-citationCostanzo, M. R., Costanzo, M. R., Dipchand, A., Starling, R., Anderson, A., Chan, M., Desai, S., Fedson, S., Fisher, P., Gonzales-Stawinski, G., et al. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.05.034 · Cited by 1,653
Self-citationImmunosuppressive Drugs for Kidney Transplantation
Halloran, P. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra033540 · Cited by 1,555
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Self-citation
Metadata
- Authors
- Eisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., Abeywickrama, K. H., & Bernhardt, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-28
- Volume
- 349
- Issue
- 9
- Pages
- 847-858
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2122783053
- Cited by
- 1,198
- References
- 26
- FWCI
- 85.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.